Alpha-1-acid glycoprotein and Pro-B-natriuretic peptide evaluation in patients with secondary pulmonary hypertension and end-stage kidney diseases receiving hemodialysis

Year 2025, Volume: 29 Issue: 1, 182 - 189

Hanan Safaa Al-waheed Raid J. Mohammed Al-timimi Arif Sami Malik Ali Ghafil Al Zaydi

Abstract

Pulmonary hypertension (PHT) is a serious condition characterized by increased blood pressure in the pulmonary arteries, leading to reduced blood flow and increased strain on the heart. Secondary PHT refers to cases where is Pulmonary hypertension a consequence of an underlying condition, and one such condition is ESRD. This work aimed to study the role of Alpha-1-acid Glycoprotein (AGP) & Pro-B-Natriuretic Peptide (BNP) in the Ddevelopment of PHT in patients under Hemodialysis. A cross-sectional observational study was conducted on 120 patients who visited the Al-Imamain Al-Khadhimain Medical City Hospital, Baghdad, Iraq, between May 2023 and July 2023 and were diagnosed with end-stage renal disease (ESRD) and underwent regular hemodialysis. Levels of AGP and BNP were measured, and clinical characteristics, including gender, age, hemodialysis duration, frequency of hemodialysis sessions per week, body mass index (BMI), and biochemical parameters such as parathyroid hormone (PTH), Ca, PO4, and albumin, were analyzed.Ca levels were significantly higher in the PHT group (8.12 ± 1.09 mg/dL) compared to the NPHT group (7.50 ± 1.10 mg/dL). AGP and BNP levels were significantly elevated in PHT patients (86.50 ± 16.54 ng/ml and 314.79±80.82 pg/ml; respectively) in comparison with NPHT group (41.98 ± 10.89 ng/ml and 211.87 ± 46.24 pg/ml; respectively). the results of the logistic regression analysis indicate that AGP has a significant positive effect on the odds of observing PHT, suggesting that higher AGP levels are associated with an increased likelihood of PHT.Patients with pulmonary hypertension who were receiving hemodialysis also had considerably higher levels of alpha-1-acid glycoprotein and pro-B-natriuretic peptide. These biomarkers might be useful resources for detecting and keeping track of pulmonary hypertension in this patient population.

Keywords

AGP, ESRD, Hemodialysis, Pro-B-Natriuretic Peptide, Pulmonary hypertension

References

• [1] Barbera JA, Roman A, Gomez-Sanchez MA, Blanco I, Otero R, LopezReyes R, Otero I, Pérez-Peñate G, Sala E, Escribano P. Guidelines on the diagnosis and treatment of pulmonary hypertension: Summary of recommendations. Arch Bronconeumol. 2018; 54: 205–215. doi: 10.1016/j.arbr.2017.11.017
• [2] Han BG, Kim J, Jung IY, Son JW. Relationship between volume status and possibility of pulmonary hypertension in dialysis naive CKD5 patients. PLoS One. 2019;14(9):e0221970. https://doi.org/10.1371/journal.pone.0221970
• [3] Genctoy G, Arikan S, Gedik O. Secondary hyperparathyroidism is associated with pulmonary hypertension in older patients with chronic kidney disease and proteinuria. Int Urol Nephrol. 2015;47(2):353-358. https://doi.org/10.1007/s11255-014-0889-5
• [4] Bolignano D, Pisano A, D'Arrigo G. Pulmonary hypertension: a neglected risk condition in renal patients? Rev Cardiovasc Med. 2018;19(4):117-121. https://doi.org/10.31083/j.rcm.2018.04.3188
• [5] Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, Zamanian RT, Elwing JM, Plomondon ME, Grunwald GK, Barón AE, Rumsfeld JS, Choudhary G. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation. 2016; 133(13): 1240-1248. https://doi.org/10.1161/circulationaha.115.020207
• [6] Rosenkranz S, Ghofrani HA, Grünig E, Klose H, Olschewski H, Hoeper MM. Cologne consensus conference on pulmonary hypertension- Update 2018. Int J Cardiol. 2018;272S:1-3. https://doi.org/10.1016/j.ijcard.2018.09.064
• [7] O'Leary JM, Assad TR, Xu M, Birdwell KA, Farber-Eger E, Wells QS, Hemnes AR, Brittain EL. Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes. Pulm Circ. 2017;7(3):674-683. https://doi.org/10.1177/2045893217716108
• [8] Nasri H. Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients. Rev Port Pneumol. 2013 ;19(5):238-239. https://doi.org/10.1016/j.rppneu.2013.05.004
• [9] Shang W, Li Y, Ren Y, Li W, Wei H, Dong J. Prevalence of pulmonary hypertension in patients with chronic kidney disease without dialysis: a meta-analysis. Int Urol Nephrol. 2018;50(8):1497-1504. https://doi.org/10.1007/s11255 018-1853-6
• [10] Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int. 2013;84(4):682-92. https://doi.org/10.1038/ki.2013.186
• [11] Suresh H, Arun BS, Moger V, Vijayalaxmi PB, Murali Mohan KTK. A prospective study of pulmonary hypertension in patients with chronic kidney disease: A new and pernicious complication. Indian J Nephrol. 2018;28(2):127-134. https://doi.org/10.4103/ijn.ijn_36_17
• [12] Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation. 2008;117(19):2475-2483. https://doi.org/10.1161/circulationaha.107.719500
• [13] Shoukat, Rehman IU, Sumera, Idrees MK, Tanweer. Pulmonary hypertension and leading factors in patients undergoing dialysis. J Coll Phys Surg Pak.2014; 24:836–839.
• [14] Rosenkranz S, Lang IM, Blindt R, Bonderman D, Bruch L, Diller GP, Felgendreher R, Gerges C, Hohenforst-Schmidt W, Holt S, Jung C, Kindermann I, Kramer T, Kübler WM, Mitrovic V, Riedel A, Rieth A, Schmeisser A, Wachter R, Weil J, Opitz CF. Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:53-62. https://doi.org/10.1016/j.ijcard.2018.08.080
• [15] Cignarelli M, Lamacchia O. Obesity and kidney disease. Nutr Metab Cardiovasc Dis. 2007;17(10):757-762. https://doi.org/10.1016/j.numecd.2007.03.003
• [16] Lima JJ. Practical ways to deal with the high burden of cardiovascular disease in hemodialysis patients. Sao Paulo Med J. 2006;124(1):36-41. https://doi.org/10.1590/s1516-31802006000100008
• [17] Ravani P, Marinangeli G, Stacchiotti L, Malberti F. Structured pre-dialysis programs: more than just timely referral? J Nephrol. 2003;16(6):862-869.
• [18] Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med. 2011;124(11):1073-80.e2. https://doi.org/10.1016/j.amjmed.2011.04.026
• [19] Stoves J, Bartlett CN, Newstead CG. Specialist follow up of patients before end stage renal failure and its relationship to survival on dialysis. Postgrad Med J. 2001;77(911):586-588. https://doi.org/10.1136/pmj.77.911.586
• [20] Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Int Med J. 2008;38(2): 101– 113. https://doi.org/10.1111/j.1445-5994.2007.01454.x
• [21] Mehta KS, Shirkande AK, Bhurke SP, Pajai AE, Swami RS, Jadhav SN. Pulmonary hypertension in various stages of chronic kidney disease in Indian patients. Indian J Nephrol. 2019;29(2):95-101. https://doi.org/10.4103/ijn.ijn_407_17
• [22] Patel P, Abraham G, Pratap B Ramalakshmi R, Mathew M, Jeevan JM, Muralidharan TR, Moorthy A, Leslie N. Clinical and biochemical parameters in chronic kidney disease with pulmonary hypertension. Indian J Nephrol. 2007; 17(1):4-6. https://doi.org/10.4103/0971-4065.35012
• [23] Emara MM, Habeb MA, Alnahal AA, Elshazly TA, Alatawi FO, Masoud AS. Prevalence of pulmonary hypertension in patients with chronic kidney disease on and without dialysis. Egypt J Chest Dis Tuberc. 2013;62(4):761-768. http://dx.doi.org/10.1016/j.ejcdt.2013.09.011
• [24] Havlucu Y, Kursat S, Ekmekci C, Celik P, Serter S, Bayturan O, Dinc G. Pulmonary hypertension in patients with chronic renal failure. Respiration. 2007; 74(5), 503–510. https://doi.org/10.1159/000102953
• [25] Mahdavi-Mazdeh M, Alijavad-Mousavi S, Yahyazadeh H, Azadi M, Yoosefnejad H, Ataiipoor Y. Pulmonary hypertension in hemodialysis patients. Saudi J Kidney Dis Transpl. 2008;19(2):189-193.
• [26] Sonkar SK, Alam M, Chandra S, Sonkar GK, Gaikwad A, Bhosale V. Association of pulmonary hypertension with ınflammatory markers and volume status in hemodialysis patients of end-stage renal disease. Cureus. 2021;13(3):e13635. https://doi.org/10.7759/cureus.13635.
• [27] Nagaraju SP, Bhojaraja MV, Paramasivam G, Prabhu RA, Rangaswamy D, Rao IR, Shenoy SV. Risk factors of pulmonary hypertension in patients on hemodialysis: A single center study. Int J Nephrol Renovasc Dis. 2021;14:487-494. https://doi.org/10.2147%2FIJNRD.S346184.
• [28] Yoo HHB, Dos Reis R, Telini WM, Telini LR, Hueb JC, Bazan SGZ, Barretti P, Martin LC, Queluz TT. Association of pulmonary hypertension with ınflammation and fluid overload in hemodialysis patients. Iran J Kidney Dis. 2017;11(4):303-308.
• [29] Hendriks PM, van de Groep LD, Veen KM, van Thor MCJ, Meertens S, Boersma E, Boomars KA, Post MC, van den Bosch AE. Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and meta-analysis. Am Heart J. 2022;250:34-44. https://doi.org/10.1016/j.ahj.2022.05.006.
• [30] Ariss RW, Alhazmi L, Nazir S, Khouri SJ, Malhotra D, Rees M, Moukarbel GV. Brain-type natriuretic peptide levels and invasive hemodynamic parameters in dialysis dependent patients. Am J Med Sci. 2023;365(3):258-262. https://doi.org/10.1016/j.amjms.2022.04.035.
• [31] Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal https://doi.org/10.1093/ndt/14.9.2178. disease. Nephrol Dial Transplant. 1999;14(9):2178-2183.